Table 1 Clinico-pathologic characteristics of PDAC patient cohort
From: Inactivation of HIPK2 attenuates KRASG12D activity and prevents pancreatic tumorigenesis
Characteristics | N | % |
|---|---|---|
Number of patients | 44 | |
Age at surgery (years) Mean ± SD | 65.8 ± 9.5 | |
Sex (Male) | 28 | 63.6 |
Site | ||
Head | 9 | 20.5 |
Body | 30 | 68.2 |
Papilla | 5 | 11.4 |
Tumor size | ||
T1 | 1 | 2.3 |
T2 | 8 | 18.2 |
T3 | 32 | 72.7 |
T4 | 1 | 2.3 |
N.D | 2 | 4.5 |
Nodal status | ||
N- | 24 | 54.5 |
N + | 20 | 45.5 |
N.D | 2 | 4.5 |
Grade | ||
1 | 3 | 6.8 |
2 | 18 | 40.9 |
3 | 23 | 52.3 |
Metastasis | ||
Absent | 43 | 97.7 |
Present | 1 | 2.3 |
HIPK2+ cells | ||
0 | 5 | 11.4 |
≤ 5 | 5 | 11.4 |
5 ≤ 20 | 8 | 18.2 |
20 ≤ 40 | 16 | 36.4 |
≥ 40 | 10 | 22.7 |